FilingReader Intelligence
Henlius doses first patient in phase 2 glomerulonephritis trial
August 6, 2025 at 09:29 AM UTC•By FilingReader AI
Shanghai Henlius Biotech has dosed the first patient in a phase 2 clinical study of HLX79 injection combined with rituximab for active glomerulonephritis in mainland China.
HLX79 is a sialidase fusion protein licensed from Palleon Pharmaceuticals, with Henlius holding exclusive China rights. Pre-clinical results suggest HLX79 enhances rituximab's B lymphocyte depletion.
No similar combination has been approved globally.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime